Cargando…

Advances in the Use of N-Acetylcysteine in Chronic Respiratory Diseases

N-acetylcysteine (NAC) is widely used because of its mucolytic effects, taking part in the therapeutic protocols of cystic fibrosis. NAC is also administered as an antidote in acetaminophen (paracetamol) overdosing. Thanks to its wide antioxidative and anti-inflammatory effects, NAC may also be of b...

Descripción completa

Detalles Bibliográficos
Autores principales: Mokra, Daniela, Mokry, Juraj, Barosova, Romana, Hanusrichterova, Juliana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526097/
https://www.ncbi.nlm.nih.gov/pubmed/37760016
http://dx.doi.org/10.3390/antiox12091713
_version_ 1785110941472391168
author Mokra, Daniela
Mokry, Juraj
Barosova, Romana
Hanusrichterova, Juliana
author_facet Mokra, Daniela
Mokry, Juraj
Barosova, Romana
Hanusrichterova, Juliana
author_sort Mokra, Daniela
collection PubMed
description N-acetylcysteine (NAC) is widely used because of its mucolytic effects, taking part in the therapeutic protocols of cystic fibrosis. NAC is also administered as an antidote in acetaminophen (paracetamol) overdosing. Thanks to its wide antioxidative and anti-inflammatory effects, NAC may also be of benefit in other chronic inflammatory and fibrotizing respiratory diseases, such as chronic obstructive pulmonary disease, bronchial asthma, idiopathic lung fibrosis, or lung silicosis. In addition, NAC exerts low toxicity and rare adverse effects even in combination with other treatments, and it is cheap and easily accessible. This article brings a review of information on the mechanisms of inflammation and oxidative stress in selected chronic respiratory diseases and discusses the use of NAC in these disorders.
format Online
Article
Text
id pubmed-10526097
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105260972023-09-28 Advances in the Use of N-Acetylcysteine in Chronic Respiratory Diseases Mokra, Daniela Mokry, Juraj Barosova, Romana Hanusrichterova, Juliana Antioxidants (Basel) Review N-acetylcysteine (NAC) is widely used because of its mucolytic effects, taking part in the therapeutic protocols of cystic fibrosis. NAC is also administered as an antidote in acetaminophen (paracetamol) overdosing. Thanks to its wide antioxidative and anti-inflammatory effects, NAC may also be of benefit in other chronic inflammatory and fibrotizing respiratory diseases, such as chronic obstructive pulmonary disease, bronchial asthma, idiopathic lung fibrosis, or lung silicosis. In addition, NAC exerts low toxicity and rare adverse effects even in combination with other treatments, and it is cheap and easily accessible. This article brings a review of information on the mechanisms of inflammation and oxidative stress in selected chronic respiratory diseases and discusses the use of NAC in these disorders. MDPI 2023-09-02 /pmc/articles/PMC10526097/ /pubmed/37760016 http://dx.doi.org/10.3390/antiox12091713 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mokra, Daniela
Mokry, Juraj
Barosova, Romana
Hanusrichterova, Juliana
Advances in the Use of N-Acetylcysteine in Chronic Respiratory Diseases
title Advances in the Use of N-Acetylcysteine in Chronic Respiratory Diseases
title_full Advances in the Use of N-Acetylcysteine in Chronic Respiratory Diseases
title_fullStr Advances in the Use of N-Acetylcysteine in Chronic Respiratory Diseases
title_full_unstemmed Advances in the Use of N-Acetylcysteine in Chronic Respiratory Diseases
title_short Advances in the Use of N-Acetylcysteine in Chronic Respiratory Diseases
title_sort advances in the use of n-acetylcysteine in chronic respiratory diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526097/
https://www.ncbi.nlm.nih.gov/pubmed/37760016
http://dx.doi.org/10.3390/antiox12091713
work_keys_str_mv AT mokradaniela advancesintheuseofnacetylcysteineinchronicrespiratorydiseases
AT mokryjuraj advancesintheuseofnacetylcysteineinchronicrespiratorydiseases
AT barosovaromana advancesintheuseofnacetylcysteineinchronicrespiratorydiseases
AT hanusrichterovajuliana advancesintheuseofnacetylcysteineinchronicrespiratorydiseases